Comera Life Sciences Holdings, Inc. financial data

Symbol
CMRA on OTC
Industry
Pharmaceutical Preparations
Location
12 Gill Street, Suite 4650, Woburn, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 64.9 %
Debt-to-equity -72.8 %
Operating Margin -914 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.7M shares +54.9%
Common Stock, Shares, Outstanding 30.7M shares +84.6%
Entity Public Float 22.6M USD
Common Stock, Value, Issued 2.76K USD +65.7%
Weighted Average Number of Shares Outstanding, Basic 23.1M shares +44.2%
Weighted Average Number of Shares Outstanding, Diluted 23.1M shares +44.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1M USD -42%
Cost of Revenue 265K USD -31.2%
Research and Development Expense 1.43M USD -7.29%
General and Administrative Expense 8.45M USD -18.5%
Operating Income (Loss) -9.15M USD +14.9%
Nonoperating Income (Expense) 138K USD
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic 3.28 USD/shares +50%
Earnings Per Share, Diluted 3.28 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.77M USD -33.8%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD +150%
Assets, Current 2.63M USD -38.7%
Property, Plant and Equipment, Net 187K USD -3.04%
Operating Lease, Right-of-Use Asset 162K USD -55.4%
Assets 3.07M USD -37.8%
Accounts Payable, Current 1.14M USD -20.3%
Accrued Liabilities, Current 1.37M USD
Liabilities, Current 2.93M USD -14.5%
Operating Lease, Liability, Noncurrent 53.7K USD
Liabilities 2.97M USD -24.5%
Retained Earnings (Accumulated Deficit) -41M USD -28.2%
Stockholders' Equity Attributable to Parent -4.22M USD -23.1%
Liabilities and Equity 3.07M USD -37.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.91M USD +33.6%
Net Cash Provided by (Used in) Financing Activities 1.58M USD +610%
Net Cash Provided by (Used in) Investing Activities -88.4K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 30.7M shares +84.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -414K USD +84.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.82M USD -33.2%
Deferred Tax Assets, Valuation Allowance 4.86M USD +293%
Deferred Tax Assets, Gross 4.96M USD +257%
Operating Lease, Liability 172K USD -53.2%
Depreciation 99.4K USD -4.17%
Payments to Acquire Property, Plant, and Equipment 88.4K USD
Lessee, Operating Lease, Liability, to be Paid 177K USD -55.1%
Property, Plant and Equipment, Gross 759K USD +14.1%
Operating Lease, Liability, Current 172K USD -12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 123K USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 123K USD -43.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.87K USD -79.2%
Operating Lease, Payments 54K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 98.2K USD -35.2%
Share-based Payment Arrangement, Expense 996K USD +110%
Interest Expense 5.97K USD -53%